In Vitro and In Vivo studies of the utility of dimethyl and diethyl carbaporphyrin ketals in treatment of cutaneous leishmaniasis

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 10, 2011, Pages 4755-4764

  Taylor, Viviana M ^a   Cedeño, David L ^b   Muñoz, Diana L ^a   Jones, Marjorie A ^b   Lash, Timothy D ^b   Young, Alexandra M ^b   Constantino, Manuel H ^b   Esposito, Nicholas ^b   Vélez, Iván D ^a   Robledo, Sara M ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b ILLINOIS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPH B; AMPHOTERICIN B; DIETHYL CARBAPORPHYRIN KETAL; DIMETHYL CARBAPORPHYRIN KETAL; MEGLUMINE ANTIMONATE; PHOTOSENSITIZING AGENT; PORPHYRIN DERIVATIVE; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CELL STRAIN U937; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA INFANTUM; LEISHMANIA PANAMENSIS; LIGHT EXPOSURE; LIPOSOMAL DELIVERY; LIVER CELL; MALE; NEUTROPHIL; NONHUMAN; PERITONEUM MACROPHAGE; PHOTODYNAMICS; PRIORITY JOURNAL; RAT; SKIN INFLAMMATION; SKIN LEISHMANIASIS; SKIN TOXICITY; SYRIAN HAMSTER; TOXICITY TESTING;

ANIMALS; ANTIPROTOZOAL AGENTS; CELLS, CULTURED; CRICETINAE; HUMANS; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; LIGHT; LIPOSOMES; MACROPHAGES, PERITONEAL; PARASITE LOAD; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; REACTIVE OXYGEN SPECIES;

EID: 80052869471     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00671-11     Document Type: Article

References (51)

1. Abreu-Silva, A. L., et al. 2004. Histopathological studies of visceralized Leishmania (Leishmania) amazonensis in mice experimentally infected. Vet. Parasitol. 121:179-187.
2. Akilov, O. E., et al. 2006. The role of photosensitizer molecular charge and structure on the efficacy of photodynamic therapy against Leishmania parasites. Chem. Biol. 13:839-847.
3. Akilov, O. E., S. Kosaka, K. O'Riordan, and T. Hasan. 2007. Parasiticidal effect of delta-aminolevulinic acid-based photodynamic therapy for cutaneous leishmaniasis is indirect and mediated through the killing of the host cells. Exp. Dermatol. 16:651-660.
4. Akilov, O. E., S. Kosaka, K. O'Riordan, and T. Hasan. 2007. Photodynamic therapy for cutaneous leishmaniasis: the effectiveness of topical phenothiaziniums in parasite eradication and Th1 immune response stimulation. Photochem. Photobiol. Sci. 6:1067-1075.
5. Allison, R. R., et al. 2004. Photosensitizers in clinical PDT. Photodiagnosis Photodyn. Ther. 1:27-42.
6. Alving, C. R., et al. 1978. Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. Proc. Natl. Acad. Sci. U. S. A. 75:2959-2963.
7. Berman, J. D. 2003. Current treatment approaches to leishmaniasis. Curr. Opin. Infect. Dis. 16:397-401.
8. Bristow, C.-A., R. Hudson, T. A. Paget, and R. W. Boyle. 2006. Potential of cationic porphyrins for treatment of cutaneous leishmaniasis. Photodiagnosis Photodyn. Ther. 3:162-167.
9. Buckner, F. S., and A. J. Wilson. 2005. Colorimetric assay for screening compounds against Leishmania amastigotes grown in macrophages. Am. J. Trop. Med. Hyg. 72:600-605.
10. Castano, A. P., T. N. Demidova, and M. R. Hamblin. 2005. Mechanisms in photodynamic therapy: part three - photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction. Photodiagnosis Photodyn. Ther. 2:91-106.
11. Chang, C. S., and K. P. Chang. 1985. Heme requirement and acquisition by extracellular and intracellular stages of Leishmania mexicana amazonensis. Mol. Biochem. Parasitol. 16:267-276.
12. Coura, S., et al. 2006. Comparison of paraffin embedded skin biopsies from different anatomical regions as sampling methods for detection of Leishmania infection in dogs using histological, immunohistological and PCR methods. BMC Vet. Res. 2:17.
13. Croft, S. L., K. Seifert, and V. Yardley. 2006. Current scenario of drug development for leishmaniasis. Indian J. Med. Res. 123:399-410.
14. Dantas Cangussú, S., et al. 2009. Histopatology of Leishmania major infection: revisiting L. major histopatology in the ear dermis infection model. Mem. Inst. Oswaldo Cruz 104:918-922.
15. Davidson, R. N., et al. 1996. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin. Infect. Dis. 22:938-943.
16. de Oliveira Cardoso, F., et al. 2010. Immunopathological studies of Leishmania amazonensis infection in resistant and in susceptible mice. J. Infect. Dis. 201:1933-1940.
17. Derycke, A. S. L. and, P. A. M. de Witte. 2004. Liposomes for photodynamic therapy. Adv. Drug Deliv. Rev. 56:17-30.
18. Dolphin, D. 1994. 1993 Syntex award lecture: photomedicine and photodynamic therapy. Can. J. Chem. 72:1005-1013.
19. Dutta, S., D. Ray, B. K. Kolli, and K. P. Chang. 2005. Photodynamic sensitization of Leishmania amazonensis in both extracellular and intracellular stages with aluminum phtalocyanine chloride for photolysis in vitro. Antimicrob. Agents Chemother. 49:4474-4484.
20. Escobar, P., I. P. Hernández, C. M. Rueda, F. Martínez, and E. Páez. 2006. Photodynamic activity of aluminum (III) and zinc (II) phthalocyanines in Leishmania promastigotes. Biomédica. 26:49-56.
21. Field, K. J., and A. Sibold. 1999. The laboratory hamster and gerbil, p. 10-11. In A. Sibold and M. Suckow (ed.), The laboratory animal pocket reference series, 1st ed. CRC Press, Washington, DC.
22. Finney, J. D. 1978. Statistical method in biological assay, 3rd ed., p. 508. Academic Press, London, United Kingdom.
23. Gagle, M. P. 1997. Photodynamic therapy with porphyrins. DermWeb, University of British Columbia, Vancouver, Canada. http://www.dermatology .org/laser/pdt.html. Accessed January 2004.
24. Gardner, D. M., et al. 2010. Association of acenaphthoporphyrins with liposomes for the photodynamic treatment of leishmaniasis. Photochem. Photobiol. 86:645-652.
25. Hayes, M. J., J. D. Spence, and T. D. Lash. 1998. Facile oxidation of a carba- porphyrin at the internal carbon atom: synthesis of novel benzo[18]annulene ketals. Chem. Commun. 1998:2409-2410.
26. Henao, H. H., Y. Osorio, N. G. Saravia, A. Gómez, and B. Travi. 2004. Efficacy and toxicity of pentavalent antimonials (Glucantime and Pentostam) in an American cutaneous leishmaniasis animal model: luminometry application. Biomédica 24:393-402. (In Spanish.)
27. Josefsen, L., and, R. W. Boyle. 2008. Photodynamic therapy: novel thirdgeneration photosensitizers one step closer? Br. J. Pharmacol. 154:1-3.
28. Kim, S. Y., E. J. Kim, and J. Park. 2002. Control of singlet oxygen-induced oxidative in Escherichia coli. J. Biochem. Mol. Biol. 35:353-357.
29. Kindhauser, M. 2003. Communicable diseases 2002: global defence against the infectious disease threat. World Health Organization, Geneva, Switzerland.
30. Kosaka, S., O. E. Akilov, K. O'Riordan, and T. Hasan. 2007. A mechanistic study of delta-aminolevulinic acid-based photodynamic therapy for cutaneous leishmaniasis. J. Invest. Dermatol. 127:1546-1549.
31. Lash, T. D., et al. 2003. Regioselective oxidations of benzocarbaporphyrins with ferric chloride: a facile synthesis of bridged [18] annulene ketals with strong absorptions in the far red and an unexpected halogenation reaction at the interior carbon atom. J. Org. Chem. 68:8558-8570.
32. Mendonça, M. G., et al. 2004. Persistence of Leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure? J. Infect. Dis. 189:1018-1023.
33. Minodier, P., and P. Parola. 2007. Cutaneous leishmaniasis treatment. Travel Med. Infect. Dis. 5:150-158.
34. Morgenthaler, J. B., et al. 2008. Carbaporphyrin ketals as potential agents for a new photodynamic therapy treatment of leishmaniasis. Bioorg. Med. Chem. 16:7033-7038.
35. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63.
36. Olmsted, J. 1979. Calorimetric determinations of absolute fluorescence quantum yields. J. Phys. Chem. 83:2581-2584.
37. Organisation for Economic Co-operation and Development. 1987. Test no. 402: acute dermal toxicity, section 4: health effects. OECD guidelines for the testing of chemicals. OECD Publishing, Paris, France. doi:10.1787/9789264070585- en.
38. Travi, B. L., and Y. Osorio. 1998. Failure of Albendazole as an alternative treatment of cutaneous leishmaniasis in the hamster model. Mem. Inst. Oswaldo Cruz 93:515.
39. Redmond, R. W., and J. N. Gamlin. 1999. A compilation of singlet oxygen yields from biologically relevant molecules. Photochem. Photobiol. 70:391-475.
40. Robledo, S., et al. 2005. In vitro and in vivo cytotoxicities and antileishmanial activities of thymol and hemisynthetic derivatives. Antimicrob. Agents Chemother. 49:1652-1655.
41. Robledo, S. M., J. A. Puerta, D. L. Muñoz, M. Guardo, and I. D. Vélez. 2006. Efficacy and tolerance of pentamidine for treatment of cutaneous leishmaniasis caused by L. (V) panamensis in Colombia. Biomédica 26:188-193.
42. Sah, J. F., et al. 2002. Genetic rescue of Leishmania deficiency in porphyrin biosynthesis creates mutants suitable for analysis of cellular events in uroporphyria and for photodynamic therapy. J. Biol. Chem. 277:14902-14909.
43. Sazgarnia, A., M. H. Bahreyni-Toosi, P. Layegh, and O. Rajabi. 2010. Liposomal zinc phthalocyanine as a potential agent for photodynamic therapy of leishmaniasis. Indian J. Dermatol. Venereol. Leprol. 76:417-418.
44. Shyam, S., and R. Madhukar. 2002. Advances in the treatment of leishmaniasis. Curr. Opin. Infect. Dis. 15:593-598.
45. Soto, J., and J. Berman. 2006. Treatment of New World cutaneous leishmaniasis with miltefosine. Trans. R. Soc. Trop. Med. Hyg. 100(Suppl. 1): S34-S40.
46. Spikes, J. D. 1992. Quantum yields and kinetics of the photobleaching of hematoporphyrin, Photofrin II, tetra(4-sulfonatophenyl)-porphine and uroporphyrin. Photochem. Photobiol. 55:797-808.
47. Sternberg, E. D., C. Brückner, and D. Dolphin. 1998. Porphyrin-based photosensitizers for use in photodynamic therapy. Tetrahedron Rep. 54:4151-4202.
48. Taylor, V. M., et al. 2010. Leishmania tarentolae: utility as an in vitro model for screening of antileishmanial agents. Exp. Parasitol. 126:471-475.
49. Voigt, A., G. Agtha, and F. Zintl. 2006. Polyunsaturated but not conjugated linoleic acid supplementation of leukemic U937 cells can act as an amplification factor for Photofrin-mediated photodynamic therapy. Photochem. Photobiol. 82:763-769.
50. World Health Organization. 2004. Scientific working group report on leishmaniasis. World Health Organization, Geneva, Switzerland. http://www.who .int/tdrold/publications/publications/swg-leish.htm.
51. 2. J. Am. Chem. Soc. 125:12803-12809.